Inclusion Criteria:
1. Relapsed or refractory follicular lymphoma (FL) (Grade 1, 2 or 3a) or marginal zone
lymphoma (MZL) histologically confirmed within 6 months of screening, as assessed by
local pathology
2. Patients should have received at least one prior therapy that includes anti-CD20 and
alkylating agent
3. Follicular lymphoma patients: Received at least one prior line of systemic therapy.
Patients that received one prior line of systemic therapy are eligible if they present
with high risk features. Patients that received two or more prior lines of systemic
therapy are eligible, assuming one of the prior lines includes anti-CD20 and
alkylating agent (as listed in criterion 2)
4. Marginal zone lymphoma patients: Received two or more prior lines of systemic therapy,
assuming one of the prior lines includes anti-CD20 and alkylating agent (as listed in
criterion 2) or relapsed after hematopoietic stem cell transplant
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
6. Adequate organ function
7. Adequate vascular access for leukapheresis procedure
Exclusion Criteria:
1. Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL, or of
transformed FL
2. WHO subclassification of duodenal-type FL
3. Central nervous system-only involvement by malignancy (subjects with secondary central
nervous system (CNS) involvement are allowed on study)
4. History of another primary malignancy that has not been in remission for at least 2
years, with the exception of non-invasive malignancies
5. Prior CAR T-cell or other genetically-modified cell therapy
6. History of or active human immunodeficiency virus (HIV)
7. Active hepatitis B or active hepatitis C
8. Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate
antibiotics or other treatment
9. Active autoimmune disease requiring immunosuppressive therapy
10. Presence of acute or chronic graft-versus-host=disease
11. History of significant cardiovascular disease
12. History or presence of clinically relevant central nervous system pathology
13. Allogenic-hematopoietic stem cell transplant (Allo-HSCT) within 90 days of
leukapheresis
Active, Not Recruiting
